Skip to main content
JIANGSU SIHUAN BIOENGINEERING CO.,LTD logo

JIANGSU SIHUAN BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000518 ISIN · CNE0000001P8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,779 across all filing types
Latest filing 2023-06-09 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 000518

About JIANGSU SIHUAN BIOENGINEERING CO.,LTD

https://www.000518shsw.com

Jiangsu Sihuan Bioengineering Co., Ltd. specializes in the research, development, and production of biopharmaceutical products and traditional Chinese medicines. The company’s core product line features genetic engineering drugs, including recombinant human interleukin-2 (rhIL-2) and recombinant human granulocyte colony-stimulating factor (rhG-CSF). Its manufacturing capabilities encompass various dosage forms such as injections, capsules, and tablets, adhering to rigorous quality standards. In addition to its pharmaceutical core, the company manages ecological restoration and landscape engineering initiatives. The organization focuses on leveraging biotechnology to provide therapeutic solutions for oncology and immune-related conditions, maintaining a commitment to scientific innovation and clinical efficacy.

Recent filings

Filing Released Lang Actions
江苏四环生物股份有限公司关于未弥补亏损达实收股本总额三分之一的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the status of accumulated losses exceeding one-third of the paid-in capital, which is a significant financial condition disclosure. It includes details about the financial situation as of December 31, 2022, reasons for the losses, and proposed measures to improve performance. The document references board and supervisory meetings but does not contain full financial statements or detailed financial analysis typical of an Annual Report or Interim Report. It is a regulatory announcement informing shareholders and the public about a material financial condition and the need for shareholder approval. The document length is short (1298 characters), and it is not a report itself but an announcement of a financial condition and related corporate actions. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for such disclosures that do not fit other specific report types.
2023-06-09 Chinese
独立董事提名人申明（刘卫）
Board/Management Information Classification · 95% confidence The document is a formal statement from the board of directors nominating an independent director candidate for the company's board. It details the qualifications, compliance with laws and regulations, and declarations regarding the nominee's eligibility and independence. There is no financial data, no mention of financial results, no discussion of management changes beyond the nomination, and no indication of a report or meeting materials. This document is an announcement related to board/management information, specifically about a nomination for a board position. Therefore, it fits best under the category of Board/Management Information (MANG). The document length and content confirm it is not a brief announcement or a report publication notice but a substantive declaration about management nomination.
2023-06-09 Chinese
江苏四环生物股份有限公司关于监事会换届选举的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the election of the supervisory board members (监事会换届选举) of 江苏四环生物股份有限公司. It details the nomination of candidates for the new supervisory board, their qualifications, and the process for election at the shareholders' meeting. There is no financial data, no mention of financial results, no audit information, and no reference to any report publication. The content is about management/board changes specifically related to the supervisory board. Therefore, this fits the category of Board/Management Information (MANG). The document length is short and it is a formal announcement, not a report or presentation.
2023-06-09 Chinese
独立董事候选人申明（刘卫）
Board/Management Information Classification · 95% confidence The document is a formal declaration by an independent director candidate of Jiangsu Sihuan Bioengineering Co., Ltd. It contains detailed statements about the candidate's qualifications, compliance with relevant laws, regulations, and stock exchange rules, and confirms the absence of conflicts of interest or disqualifications. The content is focused on governance and compliance related to board membership rather than financial results, capital changes, or shareholder voting outcomes. There is no indication that this is a report of a meeting, a financial report, or a voting result announcement. The document is a declaration related to board/management information, specifically concerning the appointment and qualifications of an independent director candidate. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length (5848 characters) supports it being a full declaration rather than a brief announcement or certification.
2023-06-09 Chinese
独立董事提名人申明（王莉）
Board/Management Information Classification · 95% confidence The document is a formal statement from the board of directors of Jiangsu Sihuan Bio Co., Ltd. nominating an independent director candidate, Wang Li. It details the candidate's qualifications, compliance with various regulatory requirements, and declarations regarding independence and eligibility. The content focuses on board/management changes and nominations rather than financial results, reports, or regulatory filings. There is no indication of financial data, earnings, or report announcements. The document is a declaration related to board management and director nomination, fitting the category of Board/Management Information (MANG). The document length (6237 characters) supports it being a full statement rather than a brief announcement or certification.
2023-06-09 Chinese
独立董事提名人申明（吴良卫）
Board/Management Information Classification · 100% confidence The document is a public statement from the board of directors nominating an independent director candidate for the company's board. It details the qualifications, compliance with laws and regulations, and declarations regarding the nominee's eligibility and independence. There is no financial data, no report of financial performance, no voting results, no meeting materials, and no mention of a report publication. The content is focused on board/management information, specifically the nomination of a board member. Therefore, the document fits best under the category of Board/Management Information (MANG). The document length is sufficient and contains detailed statements, not just an announcement or certification, so it is not RNS or RPA.
2023-06-09 Chinese

Browse filings by year

29 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.